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General Assembly of the Club Jules Gonin
Vouliagmeni, Greece
10 September 2004
President: Dr. Jack Coleman, Secretary: Dr.
Nicolas Ducrey
Club members present: 115
1) Approval of the last 2002 committe
report
Approval of the preliminary agenda of the
2004 general assembly
2) Movements in committee memberships
a) We express our gratitude to four executive
committee members, who are ending their
mandate, for their very valuable contribution
to the club:
Dr. Jack Coleman, President,
Dr. Nicolas Ducrey, Secretary,
Dr. Rosario Brancato,
Dr. Alain Gaudric.
Dr. Coleman contributed to the Club first as a
member for many years, then as Vice-
President and finally as President for a total
of 14 years in the Executive Committee. Dr.
Ducrey had a very long mandate of 22 years
as permanent Secretary of the Club. We wish
to thank both of them for the tremendous
amount of time and energy they have invest-
ed for the wellbeing of the Club Jules Gonin
Two committee members were asked to
extend their mandates for 4 years
- Dr. Zdenek Gregor
- Dr. Yasuo Tano
Dr. Zdenek Gregor is the new President Elect
Dr. Thomas J. Wolfensberger is elected as
the new Secretary of the Club
Three new committee members are elected:
- Dr. Yannick Le Mer, Montreuil, France
- Dr. Francesco Bandello, Udine, Italy
- Dr. Donald D’Amico, Boston, USA
b) The new bylaw for a four year-term of the
psesidency is accepted by the floor.
3) Movements in account memberships:
We thank Dr. Michel Gonvers, who is ending
his mandate, for his time and expertise.
Dr. Constantin Pournaras, Geneva, Switzer-
land, is elected as new account member.
4) Movements in memberships
a) Three new honorary members are elected:
- Dr. Jean-Jacques De Laey, Ghent, Belgium
- Dr. George Blankenship, Hershey, USA
- Dr. Hal Freemanm, Boston, USA
The updated number of Honorary members
is: 21
b) Eleven new passive memberships are
accepted:
- Dr. Jean-Antoine Bernard, Paris, France
- Dr. Morton S. Cox, Pickney, MI, USA
- Dr. Sergio L. Cunha, Sao Poulo, Brazil
- Dr. Gavin Douglas, Parktown, RSA
- Dr. F. Faulborn, Graz, Austria
- Dr. Froncie Gutman, Chagrin Falls, USA
- Dr. Sylvie Limon, Paris, France
- Dr. Manfred Spitznas, Bonn, Germany
- Dr. Bradley Straatsma, Los Angeles, USA
- Dr. Yuval Yassur, Tel Aviv, Israel
The updated number of passive members is:
71
c) Four resignations from membership have
been accepted:
- Dr. Hans Gnad, Viena, Austria
- Dr. Horst Laqua, Lübeck, Germany
- Dr. Helge Paulmann, Königswinter,
Germany
- Dr. Christiane Trepsat, La Mulatière,
France
d) Three members of the Club deceased this
year:
- Dr. Lorimer Fison, honorary member, on
February 12th, 2004
- Dr. James Hudson, honorary member, at
the beginning of 2004
- Dr. Sam Etzine, member from 1961–1984,
at the beginning of 2004
e) Two memberships have been withdrawn:
- Dr. Robert Sampaolesi, for non-payment of
fees
- Dr. Spiros Pollalis for non-payment of fees
and non-participation in meetings
f) Thirteen new active members are elected:
- Dr. Remzi Avci, Bursa, Turkey
- Dr. Ferdinando Bottoni, Milano, Italy
- Dr. Marta S. Figueroa, Madrid, Spain
- Dr. Glen Jaffe, Durham, USA
- Dr. Arthur Mueller, Munich, Germany
- Dr. Yuichiro Ogura, Nagoya, Japan
- Dr. Ayala Pollack, Rehovot, Israel
- Dr. Kelvin Rivett, East London, RSA
- Dr. Ingrid Scott, Miami, USA
- Dr. Cynthia A. Toth, Durham, USA
- Dr. Panagiotis Theodossiadis, Athens,
Greece
- Dr. George A. Williams, Royal Oak, USA
- Dr. Tom H. Williamson, London, UK
The updated number of active members is:
254
5) Financial reports
The financial report of the Club Jules
Gonin’s accounts and the financial report of
the 2002 Meeting in Montreux are presented
by Dr. Durcey: no special remarks.
6) Future Meetings
The 2006Meeting of the Club will take place
in Cape Town, South Africa:
The main organiser is: Dr. Louis Kruger,
Roosevelt Park, RSA
Dates of the Cape Town Meeting: Sunday
October 15th – Friday October 20th
It will be the 3rd joint meeting together with
the Retina Society
The 2008 Meeting of the Club will be held in
St. Moritz, Switzerland
The organiser is Dr. Thomas J. Wolfensber-
ger, Lausanne, Switzerland
7) Prizes of the Club Jules Gonin
The recipient of the 2004 Hermann Wacker
Prize was:
Dr. Gisèle Soubrane, Paris, France
The recipient of the 2004 Gonin Lecture of
the Retina Research Foundation was:
Dr. Leonidas Zografos, Lausanne, Switzerland
8) Miscellaneous
a) Graefe’s Archives: The journal of the Club
Jules Gonin will remain Graefe’s Archives
printed by Springer. All members will have
access to the on-line version and receive the
printed version of the journal.
b) New bylaw for membership: The following
bylaw concerning the shortening of the time
period to become a member of the Club is
accepted by the General Assembly:
- In order to become a candidate for
membership, the applicant must:
1) send his/her CV with three endorsements
from members of the Club to the Secretariat.
The documents must be received by May 1st
of the year in between congresses (odd number
year),
2) have at least 5 recent publications on
vitreoretinal subjects in Medline listed journals
with senior authorship (1st, 2nd or last author)
during the last 10 years,
3) after acceptance of the candidacy by the
Executive Committee, give at least one oral
presentation at a Club Congress within 4 years.
The membership will be voted on the next “in-
between” (od number year) Executive Com-
mittee Meeting and ratified at the following
congress of the Club Jules Gonin by the
members at the general Assembly.
A copy of the newly worde requirements for
membership will be sent o each member as
soon as ready. The bylaw discussed above is
subject to a change in the statutes article 3, 1st
paragraph, which are to be ratified in 2006 by
the General Assembly:
Current version of statutes:
Ophtalmologists and other scientists, of all
nationalities, corresponding to the conditions
of article 2a), may be eligible for the member-
ship of the Club, after having attended, as
guest, at least two meetings over a six year
period,
Modifications to be ratified:
Opthalmologists and other scientists, of all
nationalities, corresponding to the conditions
of article 2a), may be eligible for membership
of the club, after having attended, as candi-
dates, at least one meeting over a four-year
period.
c) Credit Card Payments:Members can now
pay their membership fees either with Visa or
Master Cards
Dr. Thomas J. Wolfensberger
Secretatry of the Club Jules Gonin
Meetings of the Club Jules Gonin
1959 Lausanne, Switzerland
1961 Lausanne, Switzerland
1963 Amersfoort, The Netherlands
1965 Villars-sur-Ollon, Switzerland
1966 München, Germany
1968 Cambridge, UK
1970 Lausanne, Switzerland
1972 Miami, USA
1974 La Baule, France
1976 Lausanne, Switzerland
1978 Barcelona, Spain
1980 Crans-Montana, Switzerland
1982 Cordoda, Argentina
1984 Lausanne, Switzerland
1986 Copenhagen, Denmark
1988 Brugges, Belgium
1990 Lausane, Switzerland
1992 Vienna, Austria
1994 Versailles, France
1996 Bern, Switzerland
1998 Edinburgh, Scotland, UK
2000 Taormina, Sicily
2002, Montreux, Switzerland
2004, Athens, Greece
Recipients of the Hermann Wacker
Prize
1972 Robert Machemer, Durham
1974 Rudolf Klöti, Zürich
1976 A. Oksala, Finland
1976 Jackson D Coleman, New York
1976 Karl Ossoining, Iowa City
1978 Manfred Spitznas, Bonn
1980 Donald Gass, Miami
1982 Harvey Lincoff, New York
1982 Ernst Custodis, Düsseldolf
1984 John Scott, Cambridge
1986 Relja Zivojnovic, Rotterdam
1988 Norman Byer, Torrance
1990 Charles L. Schepens, Boston
1992 Stanley Chang, New York
1994 Franz Fankhauser, Bern
1996 Pierre Amalric, Albi
1998 Alan C. Bird, London
1998 Raymond Lund, London
2000 Thomas M. Aaberg, Atlanta
2002 Steve Charles, Memphis
2004 Gisèle Soubrane, Creteil
Recipients of the Lecture of the
Retina Research Foundation
1996 Evangelos Gragoudas, Boston
1998 Peter Wiedemann, Leipzig
2000 Veit-Peter Gabel, Regensburg
2002 Joan W. Miller, Boston
2004 Leonidas Zografos, Lausanne
Members of the Executive
Committee September 2004
President Zdenek Gregor
Secretary Thomas J. Wolfensberger
Members Francesco Bandello
Rafael Cortez
Donald D’Amico
Evangelos Gragoudas
Yannick Le Mer
Einar Stefansson
Yasuo Tano
Peter Wiedemann
Honorary Members of the Club
Jules Gonin
Blankenship George, Hershey, USA
Coscas Gabriel, Créteil, France
De Laey Jean-Jacques, Ghent,
Belgium
Deutman August F., Nijmegen,
The Netherlands
Foulds Wallace, Glasgow, Scotland,
UK
Freeman Hal, Boston, USA
Gailloud Claude, Renens,
Switzerland
Klöti Rudolf, Zürich, Switzerland
Lincoff Harvey, New York, USA
Machemer Robert, Durham, USA
McPherson Alice, Houston, USA
Nakajima Akira, Bunkyo-ku, Japan
Olivela-Casals, Barcelona, Spain
Ryan Stephen, San Francisco, USA
Schepens Charles, Boston, USA
Scott John, Cambridge, UK
Shimizu Koichi, Itabashiku, Japan
Törnquist Ragnar, Örebro, Sweden
Urrets-Zavalia Alberto, Cordoba,
Argentina
Wetzig Paul, Colorado Springs,
USA
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Presentation of the 2004 Hermann Wacker
Prize to Gisèle Soubrane, MD, PhD
Gisèle Soubrane, MD, PhD (Fr) was selected by the
executive committee of the Club Jules Gonin as the re-
cipient of the Hermann Wacker Award for 2004. The
Hermann Wacker Prize is awarded to a clinician or scientist
who has provided exemplary and pioneering work in the
understanding and treatment of retinal disease. Dr.
Soubrane’s selection was based on her pioneering work
in the development of flourescein and indocyanine green
angiography in the evaluation of the retina. She has also
pioneered the use of photodynamic therapy for treating
age-related macular degeneration. Her work has played a
major role in both retinal imaging technology and in
therapeutic stragtegies for treating age-related macular
degeneration.
Dr. Soubrane qualified as a medical doctor in 1969 with
a thesis on the effect of 5 iodo 2 desoxyuridin on herpes
virus at the Medical Faculty of the University of Paris.
From 1970-1974 she spent her residency at the Department
of Ophthalmology of the University of Paris. This was
followed by a fellowship in retinal diseases under Professor
Gabriel Coscas from 1974-1976. After working for several
years at the Clinique Ophtalmologique Universitaire in
Créteil, during which she also spent time at John Hopkins
University in Baltimore, USA, as a research associate
looking at recurrent neovascularisation after blue-green
laser application, she was promoted to Associate Professor
with a specialization in Medical Retina, Angiography and
Lasers. In 1991 her research work took her to the Institute
of Ophthalmology in London to work on vascular casts in
minipigs. In 1992 she was awarded a PhD by the Faculté
des Sciences Pierre et Marie Curie of the University of
Paris for her work on “Ocular angiogenesis in normal and
pathologic eyes: Implication of basic fibrolast growth
factor”. In 1993 followed her promotion to full Professor of
Clinical Ophthalmology, and in 1996 she succeeded her
mentor, Professor Coscas, as Chair of the Department of
Ophthalmology at the University Eye Clinic in Créteil.
Gisèle’s career has been punctuated by many highlights.
She has received numerous awards internationally, such as
the Bietti Medal, the Michaelson Medal, the Médaille d’Or
CHIBRET, as well as a Senior Honor Award of the
American Academy of Ophthalmology for her clinical and
translational research. In 2000 she was also made a
Chevalier de la Légion d’Honneur, which is one of the
highest awards the French Government can bestow for
outstanding service. Gisèle’s activities in scientific societies
have also been prolific. She has served on the Executive
Committee of the Club Jules Gonin from 1992-1998 and
has acted as Chairman of the Retina Section for the
Association for Research in Vision and Ophthalmology
(ARVO). She is the past President of the European Society
for Vision and Eye Research and acts as the General
Secretary of the European Board of Ophthalmology. She
has also worked on the Board of the Société Française
d’Ophthalmologie for many years. In addition, Gisèle sits
on the editorial board of multiple journals and has been
active as a member of many national and international
societies in the field of visual science. Her research work
continues to be focused on the pathophysiology and
diagnosis of age-related macular degeneration, the natural
history of choroidal new vessels, new therapeutic
approaches for choroidal new vessels as well as experi-
mental models of age-related macular degeneration.
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In addition to all these tremendous scientific achieve-
ments, all of us know the very special gifts that make
Gisèle the individual she is. Her open smile, which makes
her instantly accessible, her sense of humour, her
tremendous energy, and last but not least her elegant
style, all mark her as a truly great person to know. It is
therefore my immense pleasure that I present this year's
Hermann Wacker Prize to Giséle Soubrane, a very special
person, scientist and clinician.
D. Jackson Coleman, MD
Past President Jules Gonin Club
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Radiotherapy has been used in ophthalmology for more
than 100 years [10]. Hilgartner (Austin, Texas, USA), in
1903, reported the first successful treatment of a retino-
blastoma by x-rays [37]. Three years later, Amman
(Winterthur, Switzerland), described the inconclusive
results of a trial of external beam radiotherapy for the
treatment of a uveal melanoma [4], and Deutschmann
(Hamburg, Germany), in 1915, reported the first successful
conservative management of this tumor by apposition of
mesothorium onto the sclera behind the tumor [20].
Progress in the use of radiotherapy in ophthalmology,
despite the inventiveness of the pioneers of this discipline,
particularly Axenfeld [7, 8] and Jendralsky [43] in
Germany, Marx [57] in Holland, and Schönberg [72],
Duncan [23], Janeway [42], and Verhoeff [90] in the
United States, was limited during the first 30 years of the
20th century [96]. During this period, when only low-
energy x-rays and natural radioisotopes were available,
treatment failures were common and complications were
often quite serious. However, the rare successes demon-
strated in spectacular fashion the efficacy of this treatment
in certain well-defined situations.
Application to ocular oncology of the technological
advances in the field of radiation physics constituted the
main source of progress in ocular radiation oncology, and
was accomplished by a series of breakthroughs.
– The use, from 1929 onwards, of radon (222Rn) seeds
for interstitial and episcleral radiotherapy of melano-
mas and retinoblastomas by Foster Moore and Stallard
in London [59, 60, 79, 80].
– The 1935 presentation to the New York Academy of
Medicine by Martin and Reese of a preliminary report
on the treatment of retinoblastomas by fractionated
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high-dose external beam radiotherapy with a device
that allowed the use of small fields and that controlled
the direction of the x-ray beam [54–56, 69].
– The successive development by Stallard and Innes, in
1948 and 1950, of radium and 60Co episcleral
applicators designed to emit high-energy gamma
radiation [40, 81, 82].
– Improvement in external beam irradiation devices with
the successive development of orthovoltage appara-
tuses (150–500 kVp), the betatron in 1941 [45], the
60Co teletherapy in 1951, and the linear accelerator in
1953 [58].
– The development by Lommatzsch, in 1968, of
106Ru/106Rh episcleral applicators that emitted high-
energy beta particles [51, 52].
– The design, by Gragoudas and colleagues in 1974, of a
device for the treatment of uveal melanomas using an
accelerated proton beam [32, 33].
– The report in 1975 by Rotman et al. [70], and the
following year that by Sealy et al. [73], of radio-
applicators loaded with Iodine 125 (125I) seeds,
developed at the Sloan-Kettering Cancer Center [36],
that emitted low-energy gamma radiation. Iodine 125
applicators were subsequently chosen by the Colla-
borative Ocular Melanoma Study (COMS) because of
their many theoretical and practical advantages for
brachytherapy [24]. They currently constitute the most
widely used treatment modality in the United States for
the conservative treatment of intraocular tumors.
– The development by Schipper, in 1982, of a system
that allows lens-sparing external beam radiotherapy by
a linear accelerator of retinoblastomas and metastases
located in the posterior segment [71].
– The recent development of conformal teletherapy and
radiotherapy delivered by a Gantry connected to a
cyclotron; applications to the field of ophthalmology
are currently under clinical evaluation.
The concept of conservative management of ocular
tumors developed in parallel with the technological
advances in radiotherapy, gradually relegated enucleation
to second place and limited the indications for which it is
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considered to be the only solution. This evidence-based
progress in treatment was facilitated greatly by concentra-
tion of the treatment of ocular tumors in specialized
centres. The history of this progress during the second half
of the 20th century has been marked by numerous
breakthroughs and landmark publications [2, 14, 21, 22,
25, 29, 30, 38, 46, 63, 64, 75, 81, 83–86, 95].
Current modalities of radiotherapy for uveal melanomas
Cobalt 60 plaques, which were the “gold standard” of
brachytherapy for uveal melanomas for a long time [98],
have now been abandoned, primarily because of concerns
regarding radioprotection. The treatments used most
widely at the present time are 106Ru/106Rh applicators,
125I applicators and proton beam radiotherapy. Other
methods and treatment modalities used by some groups
include palladium (103Pd) applicators [27] loaded with a
radioisotope that emits gamma radiation with a lower
energy than that emitted by 125I; gamma knife, which
delivers circumscribed irradiation, although with wide
diffusion around the target [47, 94]; and linear accelerator,
combined with Schipper's device [12] or a conformal
stereotactic technique [11, 93].
Ruthenium/Rhodium 106 (106Ru/106Rh) applicators
Ruthenium/Rhodium 106 applicators emit high-energy
beta particles that are able to penetrate tissues to a depth
of 6 to 7 mm, but with rapid, progressive and considerable
attenuation of the irradiation away from the radioactive
plaque. Consequently, when the tumor is prominent, the
base receives an irradiation dose several times higher than
the therapeutic dose of 90–100 Gy delivered to the apex
and, if for a mechanical reason the plaque becomes
detached from the sclera, the apex may receive an
insufficient dose of irradiation. We have estimated that,
in such a situation, the dose to the apex is reduced by about
one-half if the plaque is displaced a mere 1 mm from the
scleral wall.
The isodose configuration of the irradiation emitted by
these applicators makes them particularly suitable for the
treatment of dome-shaped melanomas that do not exceed
5 mm in thickness. The low diffusion of irradiation around
the target volume, which reduces adverse effects on the
healthy tissues that surround the tumor, and the high
irradiation dose that is delivered to the tumor base, which
induces radiation necrosis and rapid reduction of tumor
volume, thereby reducing the harmful effects produced by
the residual tumor mass, confer certain theoretical
advantages to this type of applicator. However, these
theoretical advantages are counterbalanced by a risk of
tumor recurrence, estimated to be between 10% and 40% at
5 to 15 years after treatment [53, 87, 92].
Iodine 125 (125I) applicators
Iodine 125 applicators are monodirectional brachytherapy
devices that emit low-energy gamma radiation. In the 125I
applicators designed for the COMS study, radioactive
seeds are placed in the bottom of a gold shell with walls of
3 mm thickness, which are available in several standar-
dized shapes and diameters [26]. This configuration of
radioactive sources, set at a distance from the wall of the
eyeball, helps to ensure a more homogeneous irradiation
dose delivered to the target while minimizing side scatter,
thereby ensuring better radioprotection of adjacent healthy
tissues. Dosimetry is performed with various simplified
calculation models, considering 125I seeds to be a point
irradiation source, with no correction for anisotropy [5,
6, 44].
This type of applicator, used for the treatment of
medium-sized melanomas, ensures 5- and 10-year local
tumor control rates of 85% to 95% [28, 34, 41, 68]. The
main advantage of 125I applicators is their commercial
availability, which allows all retinal surgeons working in
the field of ocular oncology to treat with a good chance of
success most small and medium-sized uveal melanomas.
The low energy of the gamma radiation emitted by these
applicators is a second advantage, as it allows effective
shielding that protects orbital tissues and also has low
ambient diffusion of radiation, thereby contributing to the
radioprotection of both patients and healthcare personnel.
However, the relatively short half-life (about two
months) of 125I is one of the major disadvantage of this
type of radioactive applicator, as it requires frequent
replacement of the seeds, which contributes to increased
cost of treatment. Furthermore, there can be difficulty in
exactly positioning the125I plaques in some cases,
especially when the tumor surrounds or covers the optic
disc, which is another disadvantage of this type of
brachytherapy, because they can result in incomplete
irradiation, possibly leading to recurrence.
Proton beam irradiation
Treatment of uveal melanomas by proton beam radiother-
apy was performed first by Gragoudas et al. in 1975 [32,
33]. Two years later, Char et al. developed a similar
radiotherapy technique using an accelerated helium ion
beam [17]; at the same time, Brovkina et al., in Moscow,
began to use a lower energy particle accelerator for the
treatment of melanomas of the iridociliary complex and
anterior choroid, without surgical localization of the tumor
[13]. We introduced proton beam irradiation into Western
Europe in 1984, in the context of a joint project between
Jules Gonin Eye Hospital and the Paul Scherrer Institut
(PSI).
The technique developed in Boston, and still used today
with only minimal modifications [67, 74, 97], comprises an
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energy modulator connected to a device that allows three-
dimensional localization of the position of the tantalum
clips fixed around the tumor base for the definition of the
target volume. Treatment planning is performed on a
computerized ocular model [31].
Treatment of uveal melanomas by accelerated proton
beam is a widely used treatment option in Europe, being
performed in Switzerland, France (Centre d'Orsay–Foun-
dation Curie, Paris; Centre Lacassagne, Nice), the United
Kingdom (Clatebridge), Italy (Catania), and Germany
(Berlin).
In Lausanne and at the PSI, between 1984 and 2004, we
have treated more than 4,000 cases of melanoma. On the
basis of the experience acquired, we have gradually
improved the local tumor control (98.8% at 10 years) and
eye retention probability (95.6% at 10 years). We have also
demonstrated, by means of subgroup analyses, the efficacy
of this treatment in specific situations, such as those
involving melanomas with extrascleral extension, melano-
mas associated with massive ocular melanocytosis, and
diffuse melanomas of the iridociliary complex. In this last
situation, due to the risk of severe dry eye syndrome
secondary to complete irradiation of the anterior segment,
we now harvest limbus stem cells prior to radiotherapy,
which are then transplanted immediately after completion
of radiotherapy.
Having achieved excellent local tumor control by
circumscribed radiotherapy, especially with accelerated
proton beam, the future objectives of conservative manage-
ment of melanoma are primarily improvement of the
functional result (elimination of the residual tumor,
decreased irradiation to adjacent healthy tissues) and
control of any microscopic metastases present at the time
of treatment. Based on the effectiveness of intrahepatic
fotemustine chemotherapy for liver metastases [50], we
have initiated a prospective study of adjuvant intrahepatic
fotemustine chemotherapy. Preliminary results of this
study for the treatment of high-risk cases (tumor diameter
≥22 mm or tumor diameter ≥15 mm with extrascleral
extension) are favourable, although the final results are still
under evaluation.
Current modalities of irradiation of retinoblastomas
Whole-eye radiotherapy and circumscribed radiotherapy
are part of the global therapeutic approach to retinoblas-
toma [9]. The choice of treatment modality, however, must
be individualized for each case, and should take into
account the extent of the tumor, the state of the fellow eye
and the risk of complications, particularly the risk for
development of a radiation-induced second orbital tumor
[1].
In the majority of complex cases, chemoreduction is
now typically the first step in treatment [30, 49, 63, 75],
and is designed to make the tumor accessible to therapies
that are less aggressive than irradiation such as photoco-
agulation, cryotherapy, or thermochemotherapy, thereby
limiting as much as possible the use of radiotherapy.
External beam radiotherapy
External beam radiotherapy is delivered by either whole-
eye irradiation techniques or lens-sparing techniques.
Regardless of delivery method, well- documented results
indicate a success rate of about 80% [39, 89].
One of the most widely used protocols consists of a total
dose of 45 Gy delivered at 2 Gy fractions per session, 5
times per week [15]. In selected cases, highly fractionated
doses can be used to reduce the risks of radiation
retinopathy [18]. In contrast, dose escalation may be
necessary, such as in the case of massive invasion of the
vitreous, although malignancies do not always respond
favourably to radiotherapy.
The current indications for external beam radiotherapy
for retinoblastoma are limited, and its use should be
avoided in children under the age of 1 year. However, this
type of treatment is justified in well-defined situations [9]:
– Primary or adjuvant therapy of advanced tumors.
– Tumors that are in contact with the optic disc after
reduction, and those that are inaccessible to brachy-
therapy or other focal treatment modalities.
– Presence of vitreous seeding that cannot be treated by
cryotherapy, brachytherapy or chemotherapy alone.
– Subretinal or vitreous seeding that is refractory to
treatment or that is recurrent after focal therapy or
chemotherapy, with or without retinal detachment in
patients with only one eye.
– Orbital exteriorization of the tumor or optic nerve
invasion after enucleation.
Two lines of research have been developed in an attempt
to limit irradiation outside of the target volume. The first
approach consists of proton beam irradiation of the entire
eye or vitreous cavity. Preliminary results have demon-
strated the effectiveness of this method in terms of local
tumor control [61, 62], but it did not eliminate the high
dose of irradiation delivered at the radiation port.
The second line of research consists of the application of
conformal radiotherapy; this is currently being studied in
Lausanne. This irradiation technique, which is guided by
three-dimensional software, employs multiple beams, each
specifically collimated. The advantage of this technique is
that it reduces considerably the irradiation dose delivered
around the target volume. Conformal radiotherapy has
already been used successfully for the treatment of various
other types of tumors [16, 48, 88, 91], and preliminary
results of its application to the treatment of retinoblastoma
are also encouraging.
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Circumscribed radiotherapy
Circumscribed radiotherapy is performed by use of either
radioactive plaques (brachytherapy) or accelerated proton
beam, after definition of the target volume by means of
tantalum clips.
The use of 60Co plaques, in which the internal surface
comprises a radius of curvature adapted to the child's eye,
was abandoned for reasons of radioprotection, even though
no case of secondary orbital tumor related to the use of
60Co plaques has been reported in the literature. In routine
clinical practice, 106Ru/106Rh plaques and 125I plaques are
used for this type of treatment. The choice between these
two types of plaque must take into account the tumor
diameter, thickness and site.
Brachytherapy is indicated for tumors with a diameter
between 4 and 15 mm and a thickness not exceeding 9 mm
[35], that cannot be treated by photocoagulation, cryo-
therapy or thermochemotherapy. Brachytherapy is indi-
cated also for treatment of residual tumors or recurrences
after external beam radiotherapy or other focal therapies
[19, 77, 78].
The recommended irradiation dose is about 40 Gy to the
apex of the tumor, in which cases local tumor control is
obtained in 80–90% of patients [3, 76, 77]. The most
commonly encountered complications are proliferative
retinopathy, radiation maculopathy, radiation neuropathy
and cataract.
Because the 40 Gy isodoses of radioactive plaques are
adapted primarily for the treatment of dome-shaped
tumors, and in view of the frequently spherical shape of
retinoblastomas, a plaque with a diameter that is quite a bit
larger than that of the tumor base must be used to include
all of the tumor. This disadvantage, together with the
technical problems of precise positioning and fixation of
radioactive plaques in young children with a posterior
tumor, has led us to the possibility of treating some
retinoblastomas by proton beam therapy after surgical
localization of the tumor with tantalum clips.
Proton beam therapy has the advantage of delivering a
homogeneous irradiation dose to a predefined target,
regardless of its shape or site inside the eyeball, which
theoretically minimizes the risk of radiation-induced
complications and increases the rate of local control.
However, with the currently available devices, which have
been adapted to the treatment of ocular tumors in adults, in
whom the head is maintained immobile in the sitting
position, we have been able to successfully treat only
children over the age of 3 years who have a recurrent
retinoblastoma.
The efficacy of this circumscribed radiotherapy, similar
to that observed for melanoma, has led us to investigate a
new device whereby radiation is delivered via a Gantry [65,
66], which directs the beam by a spot scanning technique to
children who are under general anaesthesia. This device,
which is still under construction, will likely be operational
in 2006 for experimental studies at the Institut Paul
Scherrer.
Conclusions
Considerable progress has been made in the field of
radiotherapy in ophthalmology, which now allows both
local tumor control and eye retention in the majority of
patients with a malignant intraocular tumor. However,
further progress is necessary to improve the functional
results by reducing the harmful effects of the tumor itself
and of the radiation. Combined therapies and highly
circumscribed irradiation techniques, currently under clin-
ical evaluation, are a giant step in this direction, and should
improve still more the outcome of treatment of intraocular
tumors.
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